Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 136.75M P/E - EPS this Y -14.30% Ern Qtrly Grth -
Income -29.83M Forward P/E -4.32 EPS next Y -8.30% 50D Avg Chg 4.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 33.00%
Dividend N/A Price/Book 1.21 EPS next 5Y - 52W High Chg -22.00%
Recommedations 2.00 Quick Ratio 27.31 Shares Outstanding 125.30M 52W Low Chg 116.00%
Insider Own 0.04% ROA -16.69% Shares Float 117.50M Beta 1.16
Inst Own 13.00% ROE -26.86% Shares Shorted/Prior 8.48M/7.04M Price 1.08
Gross Margin - Profit Margin - Avg. Volume 958,264 Target Price 4.58
Oper. Margin - Earnings Date Mar 28 Volume 450,656 Change -1.82%
About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atossa Therapeutics, Inc. News
03/19/24 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
03/18/24 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
03/12/24 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
03/06/24 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
03/03/24 We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
02/22/24 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
02/07/24 Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
01/22/24 Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?
01/09/24 Atossa Therapeutics Issues Letter to Shareholders
12/08/23 Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
12/04/23 Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
11/20/23 Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
11/13/23 Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
11/09/23 Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
10/30/23 Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
10/11/23 Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later
09/25/23 We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
09/18/23 Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
09/18/23 Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
08/23/23 Atossa Therapeutics backing Endoxifen in the fight against breast cancer
ATOS Chatroom

User Image Hannibal_Smith Posted - 1 hour ago

$ATOS Well let's say Mayo Clinic and Pfizer can have a nice chat at ASCO ;) @samirsss you posted a few days ago, how Pfizer acquired Thrillium, by seeing pre clinical data at a conference, if I am not mistaken? Well they can have a very good and clear look at Phase 2 data in a few weeks !

User Image TheChangedBear Posted - 6 hours ago

$ATOS Hey David! You should bring all your $HEPA earnings and bring them over to $ATOS

User Image Bunster Posted - 7 hours ago

$ATOS so 10k monday or they get an extension.

User Image Bunster Posted - 7 hours ago

$ATOS NO week in review due to easter weekend bunnys favorite holiday.

User Image CJ27969 Posted - 7 hours ago

$ATOS this is a great question from @chrundrel Here is some DD I found Hopefully you can open it https://ajronline.org/doi/pdf/10.2214/ajr.140.1.15?download=true

User Image Nailujulian Posted - 9 hours ago

$ATOS $AZN $LLY $NVS $PFE Some definitions I found for some of the big names involved in the data-release. 1.) "Contract" means a Funding Agreement that is a research and development contract that provides that the contractor perform for the benefit of the Government, with an expectation of completion of the stated research goals and the delivery of a report, data, materials or other product. Generally, Government contracts are administered under the Federal Acquisition Regulations (FAR), codified at Title 48 Code of Federal Regulations, Chapter 1 2.) "Grant" means a Funding Agreement that is an award of financial assistance which may be provided for support of basic research in a specific field of interest to the funding Federal agency (See 45 CFR Part 74, for grants from the U.S. Public Health Service.) While no specific product is anticipated, the funding agency may review the progress and direction of the funded research.

User Image OKBoomer19 Posted - 9 hours ago

$TPST $ATOS $AVTX @no_noise Appreciate "heads up" on warrants etc. One of my favorite screen moments. Into this clip 1:28 he uses his turkey call https://www.youtube.com/watch?v=DJy4XlObDzA

User Image rigpig Posted - 9 hours ago

$ATOS - Main key people / companies involved at AACR meeting What do you think will be the outcome? $PFE $LLY $AZN $NVS https://www.abstractsonline.com/pp8/#!/20272/presentation/11540 Session PO.CT02.01 - Phase II Clinical Trials 1 CT205 / 5 - Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trial M. P. Goetz, Atossa Grant/Contract Pfizer Grant/Contract. Loxo at Lilly Grant/Contract, Travel, Other, consulting with Money to Mayo. Astra Zeneca Other, consulting with Money to Mayo. Novartis Other, consulting with Money to Mayo. Atossa theapeutics Employment. Atossa Therapeutics Grant/Contract. S. Quay, Atossa Therapeutics Employment, Stock, Other Business Ownership, Patent The only company with a patent - Atossa / Dr Quay Wish you all Happy Easter and a blessed year ahead

User Image gordykroo Posted - 10 hours ago

$ATOS When did Quay start using the "kill" language? Before or after 40 to 80 dosing?

User Image Inserrato Posted - 11 hours ago

$ATOS quay is euphoric I wouldn't be surprised by a real BO

User Image Inserrato Posted - 11 hours ago

$ATOS don't sell your shares https://x.com/atossainc/status/1773451465341767924?s=20

User Image Fredminish Posted - 11 hours ago

$ATOS If anyone has good source to rank companies please share. Found dates though... 2024 Reconstitution calendar April-ranking month April is “ranking” month when the largest US companies are lined up to form the preliminary Russell US reconstitution portfolio. In 2024, the rank day will fall on Tuesday, April 30. May- and June-transition months May is the month that the preliminary reconstitution portfolio begins to be communicated to the marketplace. Beginning on May 24, preliminary lists are communicated to the marketplace and updates are provided on May 31, June 7, June 14, June 21 and June 28. The newly reconstituted indexes will take effect after the market close on 28 June 2024.

User Image Fredminish Posted - 11 hours ago

$ATOS Russell inclusion... anyone have a good way to track rankings? Where is ATOS? # Also, does anyone have the specific timeline of rank day (where they measure market cap), prelim ranking day, recon day (fourth friday in June, June 28th)? Much appreciated.

User Image Miller22 Posted - 11 hours ago

$ATOS The Good Dr is Very Smart !! Each of the seven US Food and Drug Administration-approved drugs Quay previously developed has been marketed by a company that is not his own, and that's the likely path for (Z)-endoxifen, as well. "We will develop it as if we're going to market it ourselves," he said, but added that all the while they will be assembling the elements needed to appeal to a drugmaker for licensing or acquisition. Those elements include patents, convincing Phase II data, and a Phase III trial design that the FDA has reviewed and indicated could lead to drug approval. "We're going to have Phase II data this year. The next step is to come up with a Phase III design, go to the FDA, and get approvals on those. And obviously, we'll be talking to partners along the way," Quay said.

User Image GreenBook Posted - 12 hours ago

$ATOS Hope everyone has a good weekend! See you all on Monday!

User Image Kevrolet75 Posted - 12 hours ago

$ATOS https://www.genomeweb.com/Reprint-GW23002AtossaTherapeutics

User Image no_noise Posted - 12 hours ago

$ATOS like say....endo ...will give u super powers...sterilized ur ass

User Image Nailujulian Posted - 12 hours ago

$ATOS Each of the seven US Food and Drug Administration-approved drugs Quay previously developed has been marketed by a company that is not his own, and that's the likely path for (Z)-endoxifen, as well. "We will develop it as if we're going to market it ourselves," he said, but added that all the while they will be assembling the elements needed to appeal to a drugmaker for licensing or acquisition. Those elements include patents, convincing Phase II data, and a Phase III trial design that the FDA has reviewed and indicated could lead to drug approval. "We're going to have Phase II data this year. The next step is to come up with a Phase III design, go to the FDA, and get approvals on those. And obviously, we'll be talking to partners along the way," Quay said. Read the last two sentences for a TLDR.

User Image BOVEN Posted - 12 hours ago

$ATOS absolutely solid this week. Only way is up. Wouldn’t even dream of selling

User Image DharlMorey2 Posted - 12 hours ago

$ATOS (Reshare this to the newcomers) Quay says we having a data-driven year[1] -- timeline below from Samirsss. More DD on latest catalysts [2], and our pipeline is targeting before/during/after breast cancer which is unique (great acquisition target for $PFE, $AZN , etc.). Not much more I can say -- we're ready for a strong move up on data April 5th, and conference presentation April 10. Russell 2000/3000 inclusion possible soon on preliminary list release on 4/19. [1] https://www.genomeweb.com/Reprint-GW23002AtossaTherapeutics [2] https://www.proactiveinvestors.com/NASDAQ:ATOS/Atossa-Therapeutics-Inc [3] https://atossatherapeutics.com/product-pipeline/ I predict an $AMAM or $VKTX like move!

User Image GSPfedorSilva Posted - 12 hours ago

$atos

User Image kinostreams Posted - 12 hours ago

$ATOS 👌

User Image no_noise Posted - 13 hours ago

$ATOS sometimes I think I have super powers. ..avtx predictions

User Image amiral Posted - 13 hours ago

$ATOS Really awesome 🤩 “Quay said the company currently has a three-year cash runway and is anticipating a "data-driven" year which will support advancement of (Z)-endoxifen as a monotherapy and inform decisions around development of combination therapies and other cancer indications.” I really like especially this part "data-driven" year which will support advancement of (Z)-endoxifen as a monotherapy

User Image CJ27969 Posted - 13 hours ago

$ATOS attack never came today. These pigs always know what’s going on before the common folks does. Read into it what you want. 😏. AH PR posts 🤌🏼

User Image CJ27969 Posted - 13 hours ago

$ATOS https://x.com/atossainc/status/1773451465341767924?s=46

User Image CJ27969 Posted - 13 hours ago

$ATOS https://www.genomeweb.com/Reprint-GW23002AtossaTherapeutics

User Image no_noise Posted - 13 hours ago

$ATOS our princess is going to another kingdom...how much are we setting.dowry..king wants a case of Hennessey bonus..

User Image gemininvi Posted - 13 hours ago

$ATOS https://www.genomeweb.com/Reprint-GW23002AtossaTherapeutics

User Image no_noise Posted - 13 hours ago

$ATOS just buy atos more guys..genome web is huge deal..

Analyst Ratings
HC Wainwright & Co. Buy Feb 12, 24
Cantor Fitzgerald Overweight Sep 8, 23
Ascendiant Capital Buy Sep 17, 20
Maxim Group Buy Dec 18, 19
Maxim Group Buy Jan 26, 18
Sidoti & Co. Neutral Oct 7, 13
Sidoti & Co. Buy Apr 15, 13
Dawson James Buy Mar 20, 13